Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Resumes Shipments and Procedures with AFX® and Some Sizes of AFX®2 Schedules Conference Call for December 30, 2016 at 9:00 am ET

Endologix Announces Temporary Hold on AFX to Resolve a Manufacturing Issue

Endologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System

Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium

Positive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH Symposium